Abstract
Purpose
This study aimed to investigate the prognostic significance of negative lymph nodes (NLNs) for ypN+ rectal cancer after neoadjuvant chemoradiotherapy (nCRT) and radical surgery and to construct a nomogram predicting disease-free survival (DFS).
Method
One hundred fifty-eight eligible patients were included. X-tile analysis was performed to determine cutoff values of NLNs. Clinicopathological and survival outcomes were compared. A Cox regression analysis was performed to identify prognostic factors of DFS. A nomogram was constructed and validated internally.
Results
X-tile analysis identified cutoff values of 4 and 16 in terms of DFS (χ2 = 8.129, p = 0.017). The 3-year DFS rates for low (≤ 4), middle (5–16), and high (≥ 17) NLNs group was 15.2, 55.5, and 73.1%, respectively (P = 0.017). NLN count (NLNs ≥ 17, HR = 0.400, P = 0.022), IMA nodal metastasis (HR = 1.944, P = 0.025), tumor differentiation (poor/anaplastic, HR = 1.805, P = 0.021), and ypT4 stage (HR = 7.787, P = 0.047) were independent prognostic factors of DFS. A predicting nomogram incorporating the four significant predictors was developed with a C-index of 0.64.
Conclusion
NLN count was an independent prognostic factor of DFS in patients with ypN+ rectal cancer following nCRT. A nomogram incorporating NLN count, IMA nodal metastasis, tumor differentiation, and ypT stage could stratify rectal cancer patients with different DFS and might be helpful during clinical decision-making.
Similar content being viewed by others
References
Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009; 27: 5124–30.
van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011; 12: 575–82.
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rodel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 39: 1926–33.
Glynne-Jones R. Neoadjuvant treatment in rectal cancer: do we always need radiotherapy-or can we risk assess locally advanced rectal cancer better? Recent Results Cancer Res. 2012; 196: 21–36.
Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde C, Balmana J, Regula J, Nagtegaal I, Beets-Tan R, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne C, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard J, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012; 23: 2479–516.
Leibold T, Shia J, Ruo L, Minsky B, Akhurst T, Gollub M, Ginsberg M, Larson S, Riedel E, Wong W, Guillem J. Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. J Clin Oncol. 2008; 26: 2106–11.
Okada K, Sadahiro S, Suzuki T, Tanaka A, Saito G, Kamijo A, Akiba T, Kawada S. Effects of chemoradiotherapy on lymph nodes in patients with rectal adenocarcinoma: evaluation of numbers and sizes of retrieved lymph nodes inside and outside the radiation field. Anticancer Res. 2014; 34: 4195–200.
Amin M, Edge S, Greene F, Byrd D, Brookland R, Washington M, Gershenwald J, Compton C, Hess K, Sullivan D, Jessup J, Brierley J, Gaspar L, Schilsky R, Balch C, Winchester D, Asare E, Madera M, Gress D, Meyer L, AJCC Cancer Staging Manual. 8th ed ed. 2017, New York: Springer. 252–74.
Willaert W, Mareel M, Van De Putte D, Van Nieuwenhove Y, Pattyn P, Ceelen W. Lymphatic spread, nodal count and the extent of lymphadenectomy in cancer of the colon. Cancer Treat Rev. 2014; 40: 405–13.
Damin D, Rosito M, Contu P, Tarta C, Ferreira P, Kliemann L, Schwartsmann G. Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer. J Gastrointest Surg. 2012; 16: 1573–80.
Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner G, Mino-Kenudson M, Giovannucci E, Meyerhardt J, Fuchs C. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 2010; 105: 420–33.
Wong J, Bowles B, Bueno R, Shimizu D. Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Colon rectum. 2002; 45: 1341–8.
Deng J, Liang H, Wang D, Sun D, Ding X, Pan Y, Liu X. Enhancement the prediction of postoperative survival in gastric cancer by combining the negative lymph node count with ratio between positive and examined lymph nodes. Ann Surg Oncol. 2010; 17: 1043–51.
Zhu Z, Chen H, Yu W, Fu X, Xiang J, Li H, Zhang Y, Sun M, Wei Q, Zhao W, Zhao K. Number of negative lymph nodes is associated with survival in thoracic esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Surg Oncol. 2014; 21: 2857–63.
Chen Y, Zhang L, Tian J, Ren X, Hao Q. Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients. Cancer Cell Int. 2013; 13: 6.
Ryan R, Gibbons D, Hyland J, Treanor D, White A, Mulcahy H, O'Donoghue D, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005; 47: 141–6.
Camp R, Dolled-Filhart M, Rimm D. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10: 7252–9.
Steyerberg E, Clinical prediction models: a practical approach to development, validation, and updating. 2009, New York, NY: Springer.
Habr-Gama A, Perez R, Proscurshim I, Rawet V, Pereira D, Sousa A, Kiss D, Cecconello I. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean? Dis Colon rectum. 2008; 51: 277–83.
Persiani R, Biondi A, Gambacorta M, Bertucci Zoccali M, Vecchio F, Tufo A, Coco C, Valentini V, Doglietto G, D'Ugo D. Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer. Br J Surg. 2014; 101: 133–42.
Kim H, Jo J, Lee S, Kim C, Kim Y, Kim H. Low lymph node retrieval after preoperative chemoradiation for rectal cancer is associated with improved prognosis in patients with a good tumor response. Ann Surg Oncol. 2015; 22: 2075–81.
Beresford M, Glynne-Jones R, Richman P, Makris A, Mawdsley S, Stott D, Harrison M, Osborne M, Ashford R, Grainger J, Al-Jabbour J, Talbot I, Mitchell I, Meyrick Thomas J, Livingstone J, McCue J, MacDonald P, Northover J, Windsor A, Novell R, Wallace M, Harrison R. The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol). 2005; 17: 448–55.
Kim N, Kim Y, Min B, Le EK, Sohn S, Cho C. Factors associated with local recurrence after neoadjuvant chemoradiation with total mesorectal excision for rectal cancer. World J Surg. 2009; 33: 1741–9.
Lee W, Lee S, Baek J, Lee W, Lee J, Kim N, Park Y. What does absence of lymph node in resected specimen mean after neoadjuvant chemoradiation for rectal cancer. Radiat Oncol. 2013; 8: 202.
Rullier A, Laurent C, Capdepont M, Vendrely V, Belleannée G, Bioulac-Sage P, Rullier E. Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival. Am J Surg Pathol. 2008; 32: 45–50.
McDonald J, Renehan A, O'Dwyer S, Haboubi N. Lymph node harvest in colon and rectal cancer: Current considerations. World J Gastrointest Surg. 2012; 4: 9–19.
Bhangu A, Kiran R, Brown G, Goldin R, Tekkis P. Establishing the optimum lymph node yield for diagnosis of stage III rectal cancer. Tech Coloproctol. 2014; 18: 709–17.
Mogoantă S, Calotă F, Vasile I, Crafciuc A, Gherghinescu M, Sapalidis K, Ilie D, Ion D. Histological and immunohistochemical study on sentinel lymph node in colorectal cancer - values and limitations. Rom J Morphol Embryol. 2016; 57: 65–74.
Rahbari N, Bork U, Motschall E, Thorlund K, Büchler M, Koch M, Weitz J. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2012; 30: 60–70.
George S, Primrose J, Talbot R, Smith J, Mullee M, Bailey D, du Boulay C, Jordan H, Wessex Colorectal Cancer Audit Working G. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer. 2006; 95: 841–7.
Johnson P, Porter G, Ricciardi R, Baxter N. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006; 24: 3570–675.
Popat S, Hubner R, Houlston R. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23: 609–18.
Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 2008; 14: 1413–7.
Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner G, Mino-Kenudson M, Giovannucci E, Meyerhardt J, Fuchs C. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 2010; 105: 420–33.
Kim J, Lee K, Yu C, Kim H, Kim J, Chang H, Kim J, Kim J, Kim T. The clinicopathological significance of inferior mesenteric lymph node metastasis in colorectal cancer. Eur J Surg Oncol. 2004; 30: 271–9.
Chin C, Yeh C, Tang R, Changchien C, Huang W, Wang J. The oncologic benefit of high ligation of the inferior mesenteric artery in the surgical treatment of rectal or sigmoid colon cancer. Int J Colorectal Dis. 2008; 23: 783–8.
Sun Y, Chi P, Lin H, Lu X, Huang Y, Xu Z, Huang S, Wang X. Inferior mesenteric artery lymph node metastasis in rectal cancer treated with neoadjuvant chemoradiotherapy: Incidence, prediction and prognostic impact. Eur J Surg Oncol. 2017; 43: 85–91.
Qiu H, Wu B, Xiao Y, Lin G. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. Colorectal Dis. 2011; 13: 1353–60.
Reggiani Bonetti L, Lionti S, Domati F, Barresi V. Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery? World J Gastroenterol. 2017; 28: 1412–23.
Cui J, Yang L, Guo L, Shao Y, Tan D. The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy. Oncotarget. 2017; 8: 37845–54.
Gill A, Brunson A, Lara P J, Khatri V, Semrad T. Implications of lymph node retrieval in locoregional rectal cancer treated with chemoradiotherapy: a California Cancer Registry Study. Eur J Surg Oncol. 2015; 41: 647–52.
De Stefano A, Moretto R, Bucci L, Pepe S, Romano F, Cella A, Attademo L, Rosanova M, De Falco S, Fiore G, Raimondo L, De Placido S, Carlomagno C. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom? Clin Colorectal Cancer. 2014; 13: 185–91.
Pita-Fernández S, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015; 26: 644–56.
Acknowledgements
This study was supported by National Clinical Key Specialty Construction Project (General Surgery) of China (Grant number 2012-649), Startup Fund for scientific research, Fujian Medical University (Grant number 2017XQ1028), and guiding key project of social development by the Fujian Provincial Science and Technology Department (Grant number 2015Y0058).
Author information
Authors and Affiliations
Contributions
Yanwu Sun and Pan Chi designed the study. Yanwu Sun, Yiyi Zhang, and Zhekun Huang collected the data and were major contributors in writing the manuscript. All the authors read and approved the final manuscript.
Corresponding author
Ethics declarations
This study was performed according to the ethical principles described in the Declaration of Helsinki. The institutional review board (IRB) of our hospital approved this study.
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Sun, Y., Zhang, Y., Huang, Z. et al. Prognostic Implication of Negative Lymph Node Count in ypN+ Rectal Cancer after Neoadjuvant Chemoradiotherapy and Construction of a Prediction Nomogram. J Gastrointest Surg 23, 1006–1014 (2019). https://doi.org/10.1007/s11605-018-3942-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-018-3942-3